UA82480C2 - Застосування комбінації донепезилу та мемантину для лікування хвороби альцгеймера - Google Patents
Застосування комбінації донепезилу та мемантину для лікування хвороби альцгеймера Download PDFInfo
- Publication number
- UA82480C2 UA82480C2 UA20041109789A UA20041109789A UA82480C2 UA 82480 C2 UA82480 C2 UA 82480C2 UA 20041109789 A UA20041109789 A UA 20041109789A UA 20041109789 A UA20041109789 A UA 20041109789A UA 82480 C2 UA82480 C2 UA 82480C2
- Authority
- UA
- Ukraine
- Prior art keywords
- disease
- alzheimer
- treatment
- heading
- antagonist
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims description 19
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 title abstract description 11
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 206010012289 Dementia Diseases 0.000 claims description 17
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 9
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims description 8
- 229960004640 memantine Drugs 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 6
- 208000010877 cognitive disease Diseases 0.000 claims description 5
- 229960003530 donepezil Drugs 0.000 claims description 5
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 7
- 150000001875 compounds Chemical class 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 239000005557 antagonist Substances 0.000 description 14
- 239000002552 dosage form Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 229960004136 rivastigmine Drugs 0.000 description 4
- 229960001685 tacrine Drugs 0.000 description 4
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229960003980 galantamine Drugs 0.000 description 3
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 3
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 208000009829 Lewy Body Disease Diseases 0.000 description 2
- 201000002832 Lewy body dementia Diseases 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000003930 cognitive ability Effects 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000006888 Agnosia Diseases 0.000 description 1
- 241001047040 Agnosia Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000002151 myoclonic effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000012057 packaged powder Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000004793 poor memory Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200200844 | 2002-05-31 | ||
| PCT/DK2003/000342 WO2003101458A1 (en) | 2002-05-31 | 2003-05-22 | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA82480C2 true UA82480C2 (uk) | 2008-04-25 |
Family
ID=28051666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20041109789A UA82480C2 (uk) | 2002-05-31 | 2003-05-22 | Застосування комбінації донепезилу та мемантину для лікування хвороби альцгеймера |
Country Status (9)
| Country | Link |
|---|---|
| KR (1) | KR101016927B1 (is) |
| CN (1) | CN1655793A (is) |
| AR (1) | AR040121A1 (is) |
| CA (1) | CA2426492C (is) |
| EA (1) | EA007632B1 (is) |
| IS (1) | IS7558A (is) |
| PE (1) | PE20040623A1 (is) |
| UA (1) | UA82480C2 (is) |
| ZA (1) | ZA200409147B (is) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA107653U (uk) | 2012-10-01 | 2016-06-24 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів |
| CN105294450B (zh) * | 2014-05-29 | 2024-05-17 | 广州喜鹊医药有限公司 | 具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用 |
| WO2018062941A1 (ko) * | 2016-09-30 | 2018-04-05 | 주식회사 바이오파마티스 | 도네페질 또는 그의 약학적으로 허용 가능한 염 및 메만틴 또는 그의 약학적으로 허용 가능한 염을 함유하는 치매 및 인지기능 장애 예방 또는 치료용 약학 조성물 및 이의 제조방법 |
| KR20210072569A (ko) | 2019-12-09 | 2021-06-17 | 주식회사 종근당 | 도네페질 및 메만틴을 포함하는 복합 제제 |
-
2003
- 2003-05-08 CA CA002426492A patent/CA2426492C/en not_active Expired - Fee Related
- 2003-05-22 EA EA200401617A patent/EA007632B1/ru not_active IP Right Cessation
- 2003-05-22 CN CNA038121611A patent/CN1655793A/zh active Pending
- 2003-05-22 KR KR1020047019333A patent/KR101016927B1/ko not_active IP Right Cessation
- 2003-05-22 UA UA20041109789A patent/UA82480C2/uk unknown
- 2003-05-27 AR ARP030101849A patent/AR040121A1/es unknown
- 2003-05-29 PE PE2003000527A patent/PE20040623A1/es not_active Application Discontinuation
-
2004
- 2004-11-11 ZA ZA200409147A patent/ZA200409147B/en unknown
- 2004-11-26 IS IS7558A patent/IS7558A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA007632B1 (ru) | 2006-12-29 |
| IS7558A (is) | 2004-11-26 |
| PE20040623A1 (es) | 2004-09-11 |
| CN1655793A (zh) | 2005-08-17 |
| KR20050024296A (ko) | 2005-03-10 |
| ZA200409147B (en) | 2006-06-28 |
| CA2426492A1 (en) | 2003-09-16 |
| AR040121A1 (es) | 2005-03-16 |
| KR101016927B1 (ko) | 2011-02-28 |
| EA200401617A1 (ru) | 2005-06-30 |
| CA2426492C (en) | 2006-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003227516B2 (en) | A combination of an NMDA-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease | |
| KR20050101537A (ko) | 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제 | |
| Ferreri et al. | Recent clinical trials of hydroxyzine in generalized anxiety disorder | |
| JP2000515526A (ja) | Ｍｔｐ阻害剤と他のコレステロール低下薬を組合せて使用する、血清脂質レベルの降下方法 | |
| JP2009137970A (ja) | ミルタザピンと１種類以上の選択的セロトニン再取り込み阻害剤とを含む医薬組成物 | |
| JP2008504372A (ja) | β−アミロイド関連疾患の治療のための治療用製剤 | |
| EP1732530A1 (en) | 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease | |
| KR20070007276A (ko) | 재발성 의학적 증상을 치료하기 위한 조성물 및 방법 | |
| WO2015089111A1 (en) | Novel methods | |
| US20150126464A1 (en) | Therapeutic drug and therapeutic method for neurological diseases including alzheimer's disease associated with 1,25d3-marrs | |
| CN116940362A (zh) | 在慢性ssri方案后使用苯二氮䓬增加对裸盖菇素的敏感性 | |
| ZA200507439B (en) | Use of carbamazepine derivatives for the treatment of agitation in dementia patients | |
| ZA200505143B (en) | Therapeutic formulations for the treatment of beta-amyloid related diseases | |
| US20100035927A1 (en) | Medicament for prophylactic and/or therapeutic treatment of alzheimer-type dementia | |
| MXPA05009850A (es) | Metodo para tratar el deterioro cognitivo leve y para prevenir o atrasar la enfermedad de alzheimer. | |
| UA76753C2 (uk) | Комбінація галантаміну або дезоксипеганіну та протизбуджувального агента, її застосування (варіанти) для лікування наркотичної або токсичної залежності | |
| US7884096B2 (en) | Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists | |
| US4481206A (en) | Spiro succinimide derivative in the treatment of dementia of the Alzheimer type | |
| US20120010242A1 (en) | Low dose pipamperone in treating mood disorders | |
| US10864191B2 (en) | 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity | |
| UA82480C2 (uk) | Застосування комбінації донепезилу та мемантину для лікування хвороби альцгеймера | |
| KR20020084413A (ko) | 피롤 유도체를 포함하는 약학 조성물 | |
| KR20070106729A (ko) | 메틸페니데이트 유도체 및 그 용도 | |
| EP2236157A1 (en) | Pipamperone and a second agent in treating mood and anxiety disorders | |
| CA2558708A1 (en) | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |